A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Paediatric Patients

Trial Profile

A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (non-cardiac) Surgery in Paediatric Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Fibrin (Primary) ; Oxidised cellulose
  • Indications Surgical blood loss
  • Focus Therapeutic Use
  • Sponsors Ethicon
  • Most Recent Events

    • 20 Dec 2016 Planned number of patients changed from 52 to 40.
    • 20 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019.
    • 20 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top